Media

Sunovion Media Kit

Fast Facts

Global Headquarters: Marlborough, Massachusetts, USA

Global locations: Sunovion Pharmaceuticals Inc., located in Fort Lee, New Jersey, Sunovion Pharmaceuticals Europe Ltd., based in London, England, Sunovion Pharmaceuticals Canada, Inc., based in Mississauga, Ontario, and Sunovion CNS Development Canada ULC, based in Toronto, Ontario, are wholly-owned direct subsidiaries of Sunovion Pharmaceuticals Inc.

Ownership: Indirectly, wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd.

Core Therapeutic Areas: Address serious psychiatry, neurology, and respiratory conditions

About Sunovion

Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. Sunovion’s spirit of innovation is driven by the conviction that scientific excellence paired with meaningful advocacy and relevant education can improve lives. The Company has charted new paths to life-transforming treatments that reflect ongoing investments in research and development and an unwavering commitment to support people with psychiatric, neurological, and respiratory conditions.

Key Contributions

Since 2010, Sunovion has contributed clinical advances and new treatment options, and has led advocacy and educational initiatives with cross-sector coalitions focused on the advancement of research, innovation and improvements in health care.

Advances in research innovation, treatment access, and advocacy and community outreach have included:

  • Pioneering a unique approach to discovery in the CNS space based on a systems neurobiology platform that facilitates rapid clinical development;
  • Developing and supporting leading advocacy programs, working with national advocacy partners in the U.S. including the Be Vocal: Speak Up for Mental Health, COPD Together, and Talk About It for Epilepsy! initiatives. The company has also supported hundreds of other advocacy events held regionally in the U.S., as well as in the U.K. and Canada;
  • Hosting five annual Hands On! days of service, involving hundreds of employees donating thousands of volunteer hours to the local communities in which Sunovion employees live and work.

Therapies Include

Sunovion’s track record of discovery, development and commercialization of important therapies includes Brovana® (arformoterol tartrate), Latuda® (lurasidone HCI), and Aptiom® (eslicarbazepine acetate). Approved therapies also include Utibron™ Neohaler®, Seebri™ Neohaler® and Arcapta® Neohaler®.

BROVANA is a registered trademark of Sunovion Pharmaceuticals Inc.

LATUDA is a registered trademark of Sumitomo Dainippon Pharma Co., Ltd.

APTIOM is used under license from .

UTIBRON and SEEBRI are trademarks of Novartis AG and ARCAPTA and NEOHALER are registered trademarks of Novartis AG, used under license.

Pipeline

View our clinical development pipeline.

Media Inquiries

Tel: 508-357-7740

Email: corpcomm@sunovion.com